semaglutide shortage over Ends: Compounded Versions Legal Battle Semaglutide shortage ends as FDA

Am J Physiol Cell Physiol 283 : C1056C1064 Menendez C et al

Between the high temperatures, increased sun exposure, and potential changes in activity level, your bodys needs shift in subtle but important ways

This sham-controlled randomized trial analyses whether endoscopic RFA could eradicate dysplastic BE and decrease the rate of malignant progression

The evidence cited includes the patent's listing in the FDA Orange Book, public statements by Hims's CEO on an August 2024 investor call discussing GLP-1 patent cliffs and acknowledging that semaglutide was not going off patent, and a formal demand letter sent by Novo Nordisk on February 8, 2026, one day before filing

There were no intraoperative complications, but two patients required reintervention